Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is the company's response to the short attack. I've decided to copy and paste the full.
''The report was lengthy and filled with what was positioned to be science but were actually inaccurate scientific inaccuracies and miscalculations. Below, we chose to focus on the major inaccuracies to point out the author’s flaws in the central premise. My team and I are available for a call today if needed – please let me know if you need it.
With our partner Bristol-Myers Squibb, we are developing NKTR-214 with nivolumab in 9 tumor types in over 20 registrational trials. We have a melanoma Phase 3 trial that has already been initiated and several additional registrational trials that are planned to start in renal cell carcinoma and bladder cancer by the end of the year. Clearly, the commitment of our two companies to the long-term development of the combination underscores our conviction in the combination results and our belief in the potential value of NKTR-214 and Opdivo to patients and physicians in the fight against cancer.
As we stated on our last financial results call, we look forward to presenting mature data from the fully enrolled 38-patient Stage IV melanoma cohort from PIVOT at the upcoming SITC conference in November. The data will be presented in an oral presentation on Friday, November 9th in the Cytokines Reinvented session. As data from the PIVOT cohorts mature over the next six to 18 months, Nektar and Bristol are planning to present each of the data sets at various medical meetings, including tumor-specific conferences, in the lung, melanoma, GU and breast cancer specialty areas.
The report written and issued by Plainview has a flawed central premise, contains many scientific inaccuracies, and deliberately omits published data that did not support its premise. The author did not conduct diligence with the company or the authors of peer-reviewed published data on NKTR-214. While the report is long and cites a number of references, many references are omitted and those cited are selective. As a result, we focused on the most egregious inaccuracies and omissions found in the executive summary.
The writer uses as his premise in multiple areas that lymphocyte levels following treatment with NKTR-214 did not increase sufficiently. However, the writer ignores a more complete 2018 dataset presented for NKTR-214 to make this argument. Instead, he cites 2017 data from a handful of early patients enrolled in the dose-escalation stage of the PIVOT trial (ASCO 2017) and references only a 30-50% increase in lymphocyte levels. At ASCO 2018, the company presented comprehensive lymphocyte level data for over 200 patients who were treated with the recommended Phase 2 dose of NKTR-214. The data show an increase over baseline after first cycle of >100% (achieving a level of >200% of baseline) and in subsequent cycles with NKTR-214 lymphocyte levels range up to a 200% increase over a baseline (achieving a level of 300% of baseline) which is then sustained over 10 cycles of therapy (over 200 days): Source: ASCO 2018 --- graph notes added: A: ~200% of baseline, B: ~300% of baseline
These ASCO 2018 results are concordant with what is known from the literature about lymphocyte increases following HD-IL-2. Contrary to the author’s conclusion, the pharmacodynamic effect for NKTR-214 is in fact consistent with modeling expectations for HD-IL-2. However, NKTR-214 maintains an essential difference to HD-IL-2 in that it is very-well tolerated and allows for continuous dosing (note the 10 cycles of therapy shown in the chart above). This provides a longer duration of sustained IL-2 receptor agonism and sustained increased lymphocyte levels, much longer in duration than the short increase provided by one to two cycles of HD-IL-2.
Overall Response Rate for Monotherapy HD-IL-2 vs NKTR-214
The body of selected data listed in report with high-dose IL-2 is in first-line previously untreated patients. ORR reported in the older literature vary but the studies were conducted prior to the availability of TKI therapies, BRAF therapies and checkpoint inhibitors. As is well-known, the IL-2 response rates were achieved at the expense of safety in these relatively healthy first-line patients. As an example, the author omits Phase 1 clinical data in second-line RCC patients where high-dose IL-2 was evaluated and had no responses. An important retrospective analysis by Dr. Daniel Cho (Journal of Immunotherapy 2009), highlights 28 patients who received high-dose IL-2 following treatment with TKI therapy/bevacizumab therapy. Only 3 of 28 or 11% experienced stable disease and there were no PRs or CRs (unconfirmed or otherwise). Only 1 of 23 patients could receive a second cycle of high-dose IL-2 and 26% of patients experienced severe cardiovascular toxicities, including cardiac arrest and acute pulmonary edema.
NKTR-214 was evaluated in a dose-ranging monotherapy trial in 28 patients with advanced, pre-treated cancer with a median number of prior therapies of 2 (and a range of 1-12). The breakout for pre-treatment was as follows: 16 (57.1%) had received targeted therapy; 16 (57.1%) had received an immune checkpoint inhibitor; and 6 (21.4%) had received an immune checkpoint inhibitor in addition to other immunotherapy. Tumor shrinkage was observed in 32% or 9 out of 28 patients (ranging from 2-30% tumor shrinkage), with a best response of stable disease in 50% or 14/28 patients. One patient experienced an unconfirmed partial response (a patient with advanced renal cell carcinoma who was treated with a prior TKI regimen). Another patient with pre-treated renal cell carcinoma had a 40% reduction on the right adrenal gland at the first on-treatment scan (the overall response was stable disease). Durable, stable disease > 1 year was also seen in 2 patients who continued on therapy for over one year. One patient with metastatic melanoma, previously treated with ipilimumab and a BRAF inhibitor, received 25 cycles of NKTR-214 and had durable stable disease (SD) for 15 months. A second patient with metastatic RCC, who had progressed on HD-IL-2 and was refractory to single-agent OX40 and nivolumab, was treated with 19 cycles of NKTR-214 and had durable SD for 13 months. Every patient evaluated showed evidence of immune activation and these effects were reproduced with repeated administration. Only 21% of patients experienced a G3 toxicity but these were reversible and short-lived; there were no G4/5 AEs reported. (SITC 2016, ASCO 2017 and SITC 2017)
Finally, the author quotes a paper from 2005 by Maker et al in order to disparage the combining of an IL-2 mechanism with a checkpoint inhibitor and its clinical benefit. However, the writer omits the conclusions from a later paper published by Prieto et al in 2012 which analyzed the same patients cited in the Maker study in a longer-term follow-up and highlighted the long-term clinical benefit of the combination, namely a high rate of durable complete responses achieved in these patients.
The author mis-casts the receptor-bias inherent to NKTR-214 by pulling a partial figure from a published peer-reviewed publication (2017 Charych et al PLOS ONE). If the full figure is viewed, it is clear that NKTR-214 exhibits a biased receptor occupancy favoring the IL-2 beta-gamma receptor. As a result of its bias, direct comparison of exposure (AUC) from PK evaluation of NKTR-214 active drug vs HD-IL-2 is not relevant.
Further, HD-IL-2 clears rapidly and requires TID dosing. NKTR-214 has a prodrug design with a long half-life and q3 week dosing. Given the difference in mechanisms, an analysis of PD changes, notably the increases in lymphocyte levels after drug administration (or the desired effects of dosing) is the more important measure of adequate dose administration. Nektar has highlighted achievement of this desired effect in data presented at ASCO 2018 (refer to above section on Lymphocyte Effects).
NKTR-214 was designed to avoid Treg accumulation in the tumor microenvironment. Our earliest preclinical studies demonstrated the ability to promote transient Treg elevations in the peripheral blood, but not the tumor. Inherent to its design, it is necessary to preserve some binding to IL-2R-alpha because that receptor is needed for T-cell priming reactions in the lymph node.
The statements made around TIL increases with NKTR-214 are inaccurate; in the monotherapy trial, substantial increases in intratumoral CD8+ T cells were reported with no intratumoral CD4+ T regulatory expansion (SITC 2016, ASCO 2017 and SITC 2017). These data have been published at numerous congresses.
As stated above, NKTR-214 causes elevations in lymphocytes. These elevations are seen in blood and in tumor. The fact is that substantial lymphocyte increases with NKTR-214 were observed in the periphery so this can’t be used to refute the reported TIL increases with NKTR-214 in the published data as the author attempts.
In the tumor, we have observed high concordance of TIL increases with monitoring using multiple methods; immunohistochemistry (IHC), fresh tissue flow cytometry, and T cell DNA analysis (a method that compares T cell-specific DNA vs non T cell-specific DNA to quantify the mass of T cells in tumor tissue) and all three methods have produced concordant results (manuscript in preparation). The use of several methods is critical as it important to observe concordance across these methods to increase confidence in the results.
The author uses older SITC 2016 data rather than referring to more recent publications. At ASCO 2018, Nektar reported IHC data on TIL elevations from 33 tumor biopsies in PIVOT patients at the RP2D. IHC is the most common method used in the historical literature for other agents and allows for comparison to nivolumab. The author uses a Tumeh paper to support an argument that TIL increases are observed with nivolumab. However, the author declines to point out that the Tumeh paper only demonstrates that select patients with elevated baseline TILs were able to experience a small 2-fold or less increase in TILs following nivolumab. The reality is that a 10-fold increase in TILs was observed following treatment with NKTR-214 even in patients with low baseline TILs which has not been shown with nivolumab. This is consistent with the mechanism of action of NKTR-214.
Unlike the epacadostat open label single arm trials, the PIVOT trial of NKTR-214 and Opdivo has independent blinded central data review for ORR. Nektar and BMS have stated there is a high concordance between the investigator-assessed and independent review. As the separate tumor cohorts are independently presented, such as at the upcoming SITC meeting, Nektar and BMS plan to present the investigator and independent ORR side-by-side for full transparency. The NKTR-214 and nivolumab PIVOT trial is enrolling Stage IV patients and did not enroll Stage III patients as the epacadostat studies did.
Nektar has demonstrated translational data from NKTR-214 monotherapy and the nivolumab combination studies that clearly differentiates from the mechanism of IDO inhibition. NKTR-214 promotes TIL increases, proliferation of lymphocytes (Ki67+ expressing), increases in PD-1 and ICOS expression, and increases in PD-L1 in the tumor. The MOA of NKTR-214 changes the immune system and the tumor microenvironment in a beneficial way that is non-overlapping and complementary with anti-PD1 checkpoint antibodies. We’ve observed high response rates with NKTR-214 and nivolumab in baseline PD-L1 negative patients, deepening of responses over time, and a low immune-mediated AE profile which is critically important in an I-O combination therapy.''
A neoantigen vaccine (VB10.NEO) and 214 will be tested in 10 patients with SCCHN http://www.vaccibody.com/vaccibody-announces-clinical-collaboration-agreement-with-nektar-therapeutics-for-evaluation-of-vaccibodys-personalized-cancer-neoantigen-vaccine-in-combination-with-nektars-cd-122-b/
A trial with BXCL701 (DPP 8/9 & FAP inhibitor), 214 and a PD-1 inhibitor will be underway in PDAC soon https://ir.bioxceltherapeutics.com/press-releases/detail/54/bioxcel-therapeutics-expands-immuno-oncology-partnership
Also unconfirmed reports of a preclinical collaboration with Affimed.
15% drop this week. Me thinks something not quite as rosy as predicted is causing sell off.
The CC was routine. A lot of clinical news-flow in next 6-18 months.
Nothing negative from last earning report....stock back on the move fueled in part by short covering.
No I sold awhile back because of so much inside selling
Think you're better than me?
I had this glad I took my profits after my double
21,000,000 plus shares traded and counting.
Most of the concerns are based upon a very small Phase 2 group and no control group. Yet they are still moving forward with Phase 3 trials.
https://www.forbes.com/sites/matthewherper/2018/06/02/nektar-and-bristol-hurtle-forward-with-experimental-cancer-drug/#6986c24445b6
I wouldn't try to catch the falling knife today but over the next 90 days I think the stock will recover up to the 70 area.
Some questions/concerns raised over this data released for ASCO... I think we'll be giving back most of Friday gains come Monday. Hopefully, i am sorely incorrect.
long time without any momentum... this is a new and unwelcome trend for us- where and when is that NDA filing happening?
This means BMY can now start enrolling patients in multiple pivotal trials of Opdivo + NKTR-214, as previously described.
It's official...
Nektar Therapeutics Announces Effective Date of Global Development & Commercialization Collaboration with Bristol-Myers Squibb
SAN FRANCISCO, April 3, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that the waiting period has expired under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the previously-announced Strategic Collaboration Agreement between Nektar and Bristol-Myers Squibb Company is now effective. The global development and commercialization collaboration for Nektar's CD122-biased agonist, NKTR-214, was announced on February 14, 2018.
Upon the collaboration agreement becoming effective on April 3, 2018, Bristol-Myers Squibb made a non-refundable upfront cash payment of $1.0 billion to Nektar. In addition, Bristol-Myers Squibb paid the purchase price of $850 million to Nektar for the sale and issuance by Nektar of 8,284,600 shares of its common stock to Bristol-Myers Squibb pursuant to a share purchase agreement entered into concurrently with the collaboration agreement.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly-owned R&D pipeline of investigational medicines in oncology, immunology and pain as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Contacts (for Nektar):
Investors:
Jennifer Ruddock of Nektar Therapeutics
415-482-5585
Media:
Dan Budwick of Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com
On 3/19 NKTR moves to S&P 500 from the S&P Small Cap600.
We should see some volatility as much larger S&P funds jump in during the annual rebalancing.
A consolidation at 100 would be good for the stock but presentations and interim test results could give spikes as more people and funds find out about this company.
That’s a tricky call . They have a whole bunch of other drugs, some with different partners.
Buying out the company would require a major pharma to work with other major pharma’s which I just don’t see.
Do we expect the buyout before or after June? Over or under $200/share? Interested in everyone's thoughts.
Thanks,
Thanks but I think you posted the wrong presentation.
Here is the correct one:
http://files.shareholder.com/downloads/NKTR/5852742568x0x968306/0CF92912-858E-40D4-B317-46DD676BC348/NKTR-JPMorgan_2018.pdf
First significant gap and crap this morning. The spinning top of the candlestick is there for all to see. Question remains for today is if all the buying yesterday was blow off short covering with some presentation buying or if the selling today is just profit taking by some of the funds that were here in the $20-30's.
Would expect to see some analyst price target upgrades here in the next few days. Me thinks that $74 is the short term high for the next few months.
NKTR +20% .Must be some good stuff being said
President and Chief Executive Officer, Howard W. Robin, will make a presentation at the upcoming 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2018, at 11:00 a.m. Pacific Time
The march higher continues as funds keep pouring money into the stock.
The head fake close yesterday under 50 was the set up for today big move. You didn't think all those big funds who bought the last few weeks over 50 were going to let this stock go down.
If the cancer drugs are really as good as the test results are showing, this stock could be a 5-10 bagger from these levels. Company would probably get bought out first imo.
Watch the money flow. Big boys still piling in. That cancer drug must be something special.
$NKTR breaks under 45 maybe we start our first down in a while
The two Form 4's filed here shows that the SVP's couldn't wait exercise and sell their shares. Earnings came out after market on 11/7/17 yet they were selling on 11/6, 11/7, and 11/8. Thought there was a blackout period where insiders couldn't sell shares within 5 days of earnings.
They turned out to be wrong as well as the stock took off and they lost potential profits.
Lol Abe been here no brainer
Finally this stock has broken out of it's base...owned it a long time ....since the Afrezza days.....
Booooooooom im back on it.....
Booooooom im back on it.
Up she goed
Nice trafding 30$ soon...
This one is a keeper starkd
Glad I put 11k in here yeehaw...nice hedge with my mmj plays
These analysts upgrading to the sky only for them to support a secondary at 1/4 of price..typical bio pump after any level of success
Followers
|
36
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
300
|
Created
|
10/20/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |